Market Place
Sourcing Support
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
24 May 2024 //
GLOBENEWSWIRE
OpGen Announced 1-for-10 Reverse Stock Split
16 May 2024 //
GLOBENEWSWIRE
OpGen Provides Update on Business Operations and Strategic Opportunities
29 Apr 2024 //
GLOBENEWSWIRE
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
23 Apr 2024 //
GLOBENEWSWIRE
OpGen Announces Acquisition of Preferred Stock by David Lazar
25 Mar 2024 //
GLOBENEWSWIRE
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 2023 //
GLOBENEWSWIRE
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million
12 Oct 2023 //
GLOBENEWSWIRE
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 2023 //
GLOBENEWSWIRE
OpGen™s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
07 Aug 2023 //
GLOBENEWSWIRE
OpGen to Provide Business Update & Financial Results for the Second Quarter 2023
03 Aug 2023 //
GLOBENEWSWIRE
OpGen™s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
03 Aug 2023 //
GLOBENEWSWIRE
Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
19 Jul 2023 //
GLOBENEWSWIRE
OpGen Subsidiary Ares Genetics Maintains Key Patent under Opposition in Europe
26 Jun 2023 //
GLOBENEWSWIRE
OpGen Presents Unyvero Urinary Tract Infection Panel Trial at ASM Microbe 2023
20 Jun 2023 //
GLOBENEWSWIRE
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
OpGen to Provide Business Update and Financial Results for the 1Q 2023
08 May 2023 //
GLOBENEWSWIRE
OpGen Announces Closing of $3.5 Million Public Offering
04 May 2023 //
GLOBENEWSWIRE
OpGen Announces Pricing of $3.5 Million Public Offering
01 May 2023 //
GLOBENEWSWIRE
OpGenâ Subsidiary Curetis Meets All Remaining Key Milestones in R&D
26 Apr 2023 //
GLOBENEWSWIRE
OpGen Submits De Novo request to the U.S. FDA for Unyvero UTI Panel
18 Apr 2023 //
GLOBENEWSWIRE
OpGen Enters Into Distribution Agreement for Unyvero in the U.S
18 Apr 2023 //
GLOBENEWSWIRE
OpGen`s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
05 Apr 2023 //
GLOBENEWSWIRE
OpGen Reports 4Q and Full Reports Full 2022 FYR and Provides Business Update
30 Mar 2023 //
GLOBENEWSWIRE
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
OpGen to Provide Financial Results for the Fourth Quarter and Full Year 2022
22 Mar 2023 //
GLOBENEWSWIRE
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location
01 Mar 2023 //
GLOBENEWSWIRE
OpGen Announces Exercise of All Prefunded Warrants
17 Feb 2023 //
GLOBENEWSWIRE
OpGen subsidiary Ares Genetics announces granting of key patent in China
26 Jan 2023 //
GLOBENEWSWIRE
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
18 Jan 2023 //
GLOBENEWSWIRE
OpGen Subsidiary Curetis Meets Several Milestones in FIND Collaboration Project
17 Jan 2023 //
GLOBENEWSWIRE
OpGen Announces Closing of $7.5 Million Public Offering
11 Jan 2023 //
GLOBENEWSWIRE
OpGen Announces Pricing of $7.5 Million Public Offering
06 Jan 2023 //
GLOBENEWSWIRE
OpGen Announced 1-for-20 Reverse Stock Split
04 Jan 2023 //
GLOBENEWSWIRE
OpGen Announces Data from Trial for Unyvero Urinary Tract Infection Panel
13 Dec 2022 //
GLOBENEWSWIRE
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 2022 //
GLOBENEWSWIRE
OpGen Announces Unaudited Revenue and Cash Position for Third Quarter 2022
27 Oct 2022 //
GLOBENEWSWIRE
OpGen to Provide Business Update &Financial Results for the Third Quarter 2022
27 Oct 2022 //
GLOBENEWSWIRE
OpGen Subsidiary Curetis and BioVersys Sign Agreement for Trial Support
25 Oct 2022 //
GLOBENEWSWIRE
OpGen Announces Successful Completion of Trial Enrollment for UnyveroUTIs
03 Oct 2022 //
GLOBENEWSWIRE
OpGen Announces Closing of $3.38 Million Registered Direct Offering
03 Oct 2022 //
GLOBENEWSWIRE
OpGen Announces $3.38 Million Registered Direct Offering
30 Sep 2022 //
GLOBENEWSWIRE
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement
20 Sep 2022 //
GLOBENEWSWIRE
OpGen Announces Participation at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
31 Aug 2022 //
GLOBENEWSWIRE
OpGen Launches Ares Sequencing Services in the U.S.
25 Aug 2022 //
GLOBENEWSWIRE
OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
OpGen to Provide Financial Results for the Second Quarter 2022
28 Jul 2022 //
GLOBENEWSWIRE
Ares Genetics Enters into Collaboration Agreement with BNGC
26 Jul 2022 //
GLOBENEWSWIRE
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Q2 2022
08 Jul 2022 //
GLOBENEWSWIRE
OpGen Enrolls 1,000th Patient in Trial for Unyvero UTI Panel
22 Jun 2022 //
GLOBENEWSWIRE
OpGen Announces Publication of Results of Unyvero HPN Panel
22 Jun 2022 //
GLOBENEWSWIRE
Curetis, Leader Life Sciences Enter into Unyvero Distribution Partnership
09 Jun 2022 //
GLOBENEWSWIRE
OpGen Announces Publication of Results from Study Using Unyvero HPN Panel
26 May 2022 //
GLOBENEWSWIRE
OpGen to Provide Business Update and Financial Results for First Quarter 2022
28 Apr 2022 //
GLOBENEWSWIRE
OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure
25 Apr 2022 //
GLOBENEWSWIRE
Ares Genetics Commercially Launches Sequencing and Analysis Services Globally
20 Apr 2022 //
GLOBENEWSWIRE
OpGen`s subsidiary Ares Genetics provides update on collaboration agreement
06 Apr 2022 //
GLOBENEWSWIRE
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
OpGen to and Financial Results for the Q4 and FY 2021
15 Mar 2022 //
GLOBENEWSWIRE
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
10 Feb 2022 //
GLOBENEWSWIRE
